Reimbursement Decisions Logo
Guest | Login/Register
Your foremost guide to global pricing and reimbursement decisions.TM

Canadian Drug Review Reimbursement Decision


Back to Decisions Master Page
  Finacea
Generic Azelaic acid
Company Bayer Inc.
Indication rosacea
Condition Skin and subcutaneous tissue
Submission Type
Patient Population Azelaic acid has a Health Canada indication for the treatment of inflammatory papules and pustules and erythema of mild-to-moderate rosacea. Azelaic acid has antikeratinizing and antibacterial properties, but its mechanism of action in rosacea is unknown. It is available as a 15% topical gel, and the Health Canada-approved dose is 0.5 g applied twice daily.
Status Complete
Date of Recommendation 2011-02-16
Recommendation Summary List
Recommendation Details The Canadian Expert Drug Advisory Committee (CEDAC) recommends that azelaic acid 15% gel be listed.
Reason for Recommendation In two randomized controlled trials (RCT) azelaic acid 15% gel had similar efficacy compared with metronidazole, as either 0.75% or 1% gel, for patients with mild-to-moderate papulopustular rosacea in terms of reduced lesion count and investigator assessed global severity. Of Note: Azelaic acid 15% gel is similar in cost to metronidazole 0.75% gel, but more costly than metronidazole 1% gel, when all three products are applied at the frequencies recommended in the product monographs.
Clinical Report:
Pharmacoeconomic Report:
Final Recommendation Report: CDR clinical report  CADTH-CDR Final Recommendation report

†The information referenced on this page is compiled from publicly available documents published by CADTH and is available through the embedded links.


Back to Decisions Master Page